Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss and impaired angiogenesis

Glucocorticoid (GC) induced osteoporosis (GIOP) and osteonecrosis remain a significant health issue with few approved therapies. Here, we investigate the cellular and molecular processes by which GCs affect osteogenesis and angiogenesis. We find that GC treatment reduces bone mass through decreased bone formation by skeletal stem cells (SSCs). Concomitantly, endothelial cells increase in number but display distorted phenotypical features. Transplantation studies of SSCs combined with molecular analysis by single cell RNA-sequencing and functional testing of primary human cells tie GC-induced skeletal changes to altered stem cell differentiation dynamics. This in turn perpetuates reduced osteogenesis and vascular malformation through direct SSC-endothelial crosstalk mediated at least in part by Basigin. The genetic deletion of Basigin in the skeletal lineage as well as antibody-mediated blockade of Basigin during GC treatment prevents bone loss. Intriguingly, when administered to 2-year-old mice, anti-Basigin therapy reinstates bone remodeling to significantly improve bone mass. These findings provide therapeutic vantage points for GIOP and potentially other conditions associated with bone loss.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-08-15
DOI
https://doi.org/10.1038/s41467-025-62881-w
Citations
1
Primary Topic
Signaling Pathways in Disease
Type
article
Field-Weighted Citation Impact
0.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss and impaired angiogenesis

Fernando Sigler Chávez, Kelly C. Weldon, Thomas H. Ambrosi, J. Kent Leach et al.
1 citations
Nature Communications
Signaling Pathways in Disease
0.81
article

Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss and impaired angiogenesis

Fernando Sigler Chávez, Kelly C. Weldon, Thomas H. Ambrosi, J. Kent Leach, Fernando A. Fierro, Nancy E. Lane, Charles K. F. Chan, David L.S. Morales, Augustine M. Saiz, Eleanor A. Hunt, Matthew P. Murphy, Amin Cressman, Erika E. Wheeler, Kun Chen, Liming Zhao, Luke Wang, Yuting Wang, Amber N Maifeld
article en
1 citations

Abstract

Glucocorticoid (GC) induced osteoporosis (GIOP) and osteonecrosis remain a significant health issue with few approved therapies. Here, we investigate the cellular and molecular processes by which GCs affect osteogenesis and angiogenesis. We find that GC treatment reduces bone mass through decreased bone formation by skeletal stem cells (SSCs). Concomitantly, endothelial cells increase in number but display distorted phenotypical features. Transplantation studies of SSCs combined with molecular analysis by single cell RNA-sequencing and functional testing of primary human cells tie GC-induced skeletal changes to altered stem cell differentiation dynamics. This in turn perpetuates reduced osteogenesis and vascular malformation through direct SSC-endothelial crosstalk mediated at least in part by Basigin. The genetic deletion of Basigin in the skeletal lineage as well as antibody-mediated blockade of Basigin during GC treatment prevents bone loss. Intriguingly, when administered to 2-year-old mice, anti-Basigin therapy reinstates bone remodeling to significantly improve bone mass. These findings provide therapeutic vantage points for GIOP and potentially other conditions associated with bone loss.

Nature CommunicationsVol. 16(1)
California Institute for Regenerative Medicine (US), University of California Davis Medical Center (US), University of California, Davis (US), Stanford University (US)
Prostate Cancer Foundation, Arthritis National Research Foundation, California Institute of Regenerative Medicine, National Research Foundation, National Institutes of Health, University of Illinois at Urbana-Champaign, University of California, Davis, National Institute on Aging
Openalex Percentile: Top 25%
Signaling Pathways in Disease
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.